Thys-Jacobs Susan, McMahon Don, Bilezikian John P
Division of Endocrinology, Department of Medicine, St. Luke's-Roosevelt Hospital, College of Physicians and Surgeons, Columbia University Medical Center, New York, NY, USA.
Am J Obstet Gynecol. 2008 May;198(5):506.e1-8. doi: 10.1016/j.ajog.2007.11.005. Epub 2008 Jan 15.
Recent evidence suggests that abnormalities in calcium metabolism may be responsible for the luteal phase symptoms in women experiencing premenstrual syndrome. Our objective was to measure the cyclic variations in bone turnover across the menstrual cycle in women with and without luteal phase symptoms consistent with severe premenstrual syndrome or premenstrual dysphoric disorder.
We measured the indices of bone metabolism, N-telopeptide, osteocalcin and insulin-like growth factor-1 in women with and without premenstrual dysphoric disorder using a cross-sectional and prospective design. Participating women underwent 2 months of self-assessment symptom screening and 1 month of hormonal evaluation.
Overall serum insulin-like growth factor-1 (mean +/- standard deviation) was significantly lower in the premenstrual dysphoric disorder group compared with controls (205.7 +/- 56.8 vs 240.2 +/- 76.9 ng/ mL, P = .01) and was significantly lower throughout all 5 phases of the menstrual cycle in the premenstrual dysphoric disorder group compared with controls. In both groups of women, serum insulin-like growth factor-1 concentrations were highest and urinary N-telopeptide levels were lowest during the luteal phase. Bone remodeling indices of formation and resorption during the menstrual cycle were greater and appeared earlier in the control compared with the premenstrual dysphoric disorder group.
Significantly lower insulin-like growth factor-1 concentrations in premenstrual dysphoric disorder subjects compared with controls may hold insights about how premenstrual dysphoric disorder subjects differ from asymptomatic controls.
近期证据表明,钙代谢异常可能是经前期综合征女性黄体期症状的原因。我们的目的是测量有和没有与严重经前期综合征或经前期烦躁障碍一致的黄体期症状的女性在整个月经周期中骨转换的周期性变化。
我们采用横断面和前瞻性设计,测量了有和没有经前期烦躁障碍的女性的骨代谢指标、N-端肽、骨钙素和胰岛素样生长因子-1。参与研究的女性进行了2个月的自我评估症状筛查和1个月的激素评估。
与对照组相比,经前期烦躁障碍组的总体血清胰岛素样生长因子-1(均值±标准差)显著降低(205.7±56.8 vs 240.2±76.9 ng/mL,P = 0.01),并且在月经周期的所有5个阶段中,经前期烦躁障碍组均显著低于对照组。在两组女性中,黄体期血清胰岛素样生长因子-1浓度最高,尿N-端肽水平最低。与经前期烦躁障碍组相比,对照组在月经周期中骨形成和骨吸收的重塑指标更高且出现更早。
与对照组相比,经前期烦躁障碍受试者的胰岛素样生长因子-1浓度显著降低,这可能有助于了解经前期烦躁障碍受试者与无症状对照组的差异。